Disseminated Crusted Scabies After Rituximab in a Patient With Systemic Sclerosis-Lupus Overlap - Summary - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Disseminated Crusted Scabies Following Rituximab Therapy in a Patient With Systemic Sclerosis–Lupus Overlap Syndrome

  • November 3, 2026

Share

Objective:

To report crusted scabies in an immunosuppressed adolescent with systemic sclerosis–systemic lupus erythematosus overlap syndrome after rituximab therapy.

Approach:
  • Presentation: A 17-year-old girl presented with four months of progressive skin scaliness, generalized pruritus, and recurrent finger gangrene after receiving rituximab, methotrexate, and high-dose prednisolone for one month.
  • Diagnosis: Examination showed widespread thick, yellowish-brown hyperkeratotic crusts. Skin scraping identified Sarcoptes scabiei mites and ova, confirming crusted scabies.
  • Treatment: She received oral ivermectin on days 1, 2, 8, 9, 15, 22, and 29; topical permethrin; intravenous antibiotics for a bacterial finger infection; and empirical intravenous immunoglobulin. Family members received single-dose ivermectin.
Key Findings:
  • The patient had generalized crusted scabies and infected digital gangrene.
  • Marked clinical improvement was documented five months after treatment.
  • Family members had similar but less severe symptoms without dissemination.
Interpretation:

The authors state that rituximab-associated B-cell depletion likely compromised mite clearance and allowed hyperinfestation. They note that crusted scabies warrants consideration in immunosuppressed patients with refractory dermatitis, including those without classic burrows.

Limitations:
  • This is a single-patient case report.
  • Serum IgG was not measured before intravenous immunoglobulin was administered.

Original Source(s)

Related Content